Sana Biotechnology (SANA) Competitors

Sana Biotechnology (NASDAQ:SANA) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Which has more risk and volatility, SANA or XENE?

Sana Biotechnology has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.

Do insiders & institutionals have more ownership in SANA or XENE?

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 95.4% of Xenon Pharmaceuticals shares are held by institutional investors. 31.1% of Sana Biotechnology shares are held by insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media favor SANA or XENE?

In the previous week, Xenon Pharmaceuticals had 29 more articles in the media than Sana Biotechnology. MarketBeat recorded 38 mentions for Xenon Pharmaceuticals and 9 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 0.52 beat Xenon Pharmaceuticals' score of 0.21 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	10 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has higher earnings and valuation, SANA or XENE?

Xenon Pharmaceuticals has higher revenue and earnings than Sana Biotechnology. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$266.76M	-$1.06	-3.26
Xenon Pharmaceuticals	$7.50M	384.09	-$234.33M	-$3.55	-10.52

Do analysts recommend SANA or XENE?

Sana Biotechnology presently has a consensus target price of $8.00, suggesting a potential upside of 131.21%. Xenon Pharmaceuticals has a consensus target price of $53.20, suggesting a potential upside of 42.40%. Given Sana Biotechnology's higher probable upside, analysts plainly believe Sana Biotechnology is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Xenon Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is SANA or XENE more profitable?

Xenon Pharmaceuticals' return on equity of -38.50% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-91.96%	-43.07%
Xenon Pharmaceuticals	N/A	-38.50%	-36.47%

Summary

Xenon Pharmaceuticals beats Sana Biotechnology on 7 of the 13 factors compared between the two stocks.